naa a22 4500 51076424X CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130501xx s 000 0 eng 10.1007/s12094-012-0929-5 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0929-5 MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications [Elektronische Daten] [Wei Tian, Junqing Chen, Haifei He, Yongchuan Deng] Breast cancer is the most common malignancy and leading cause of cancer mortality in women. Drug resistance is a major obstacle in systemic therapy of breast cancer, which leads therapeutic failure, incontrollable disease, and mortality. MiRNAs are an emerging field in cancer research. Recent evidence demonstrates that miRNAs are core regulators in drug resistance of breast cancer. Preclinical research reveals that miRNAs modulate the multidrug-resistant signal transduction network through up-regulated drug efflux transporters and anti-apoptotic proteins, acquisition of epithelial-mesenchymal transition, and formation of cancer stem cells. MiRNAs mediate endocrine resistance through modulating ERα expression, receptor tyrosine kinase signaling, cell survival signaling, and apoptosis. Such emerging evidence indicates that miRNAs could be potential biomarkers for predicting a response to systemic therapy and prognosis in clinical settings. Targeting specific miRNAs of the drug-resistant network is promising in overcoming drug resistance in breast cancer. Federación de Sociedades Españolas de Oncología (FESEO), 2012 miRNA nationallicence Breast cancer nationallicence Multidrug resistance nationallicence Endocrine resistance nationallicence Biomarker nationallicence Tian Wei Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut Chen Junqing Department of Chemotherapy, Zhejiang Cancer Hospital, 310022, Hangzhou, China aut He Haifei Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut Deng Yongchuan Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut Clinical and Translational Oncology Springer Milan 15/5(2013-05-01), 335-342 1699-048X 15:5<335 2013 15 12094 https://doi.org/10.1007/s12094-012-0929-5 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0929-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tian Wei Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut NATIONALLICENCE 700 1- Chen Junqing Department of Chemotherapy, Zhejiang Cancer Hospital, 310022, Hangzhou, China aut NATIONALLICENCE 700 1- He Haifei Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut NATIONALLICENCE 700 1- Deng Yongchuan Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/5(2013-05-01), 335-342 1699-048X 15:5<335 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer